Impact Factor
3.70
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.37
1,360 total citations
h5-index
37
h5 depth signal
Cited share
78.3%
358 of 457
Total citations
1,360
Citation footprint
Metric signal
3.29
External metric anchor
Self-citation
4.9%
66 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
China
427
United States
342
Italy
309
United Kingdom
105
Spain
89
Citing Fields of Research
Pharmacology & Toxicology
386
Medical Ethics
247
Oncology
165
Cardiology
162
Diabetes
118
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
3,037
Articles tracked across the journal lifetime
Indexed publication set
457
358 cited publications
Last 12 months
78
6.5 publications/month
Open access share
16.7%
13 OA publications in the last year
Leading citing country
China
427 citing publications
Leading citing field
Pharmacology & Toxicology
386 citing publications
Latest tracked publication
3 October 2026
10 recent records available
Coverage & Indexing History
v1n1, May 2002-
v1n1, May 2002-
Active Coverage
Research Focus & Classification
Indexed Subjects
Pharmacology & Toxicology
Cardiology
Medical Ethics
Diabetes
Oncology
Immunology
Broad Categories
Drug Therapy
Pharmacology
Medical Ethics
MeSH Descriptors
Consumer Product Safety
Drug Evaluation
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Product Surveillance, Postmarketing
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1080/14740338.2026.2742174
Open DOI
Long-term safety of treatment of hemophilia A: a comprehensive review
02
DOI 10.1080/14740338.2026.2735075
Open DOI
Tolerance of methotrexate co-administered with pegloticase in patients with uncontrolled gout: overview of the findings from the mirror RCT
1. Pegloticase is an infused polyethylene glycol (PEG)–ylated uricase enzyme approved by the US Food and Drug Administration for treatment of patients with uncontrolled gout who do not respond to o...
03
DOI 10.1080/14740338.2026.2734464
Open DOI
A safety review of JAK inhibitors for managing alopecia areata
1. Advances in understanding alopecia areata (AA) pathogenesis have identified the collapse of hair follicle immune privilege and subsequent activation of the Janus kinase–signal transducer and act...
04
05
DOI 10.1080/14740338.2026.2721396
Open DOI
Safety of treatments for children with functional constipation
Functional constipation (FC) in children is a common diagnosis that can be challenging to treat effectively. Internet and social media are shaping parental knowledge and beliefs has become of great importance. A literature review was con...
06
DOI 10.1080/14740338.2026.2718746
Open DOI
Early recognition, prevention, and management of glucocorticoid toxicity in patients with rheumatic diseases
1. Glucocorticoids (GCs), also known as corticosteroids or steroids, were first discovered as compound E or cortin. Hench PS et al. coined the term cortisone and were also the first to study it for...
07
DOI 10.1080/14740338.2026.2719768
Open DOI
Lesser-known medication safety considerations in sickle cell disease
1. Sickle cell disease (SCD) is a rare inherited blood disorder affecting at least 100,000 individuals in the United States and several million people worldwide [1,2]. There are multiple different ...
08
DOI 10.1080/14740338.2026.2719047
Open DOI
Myositis in cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION–ARON-017 systematic review and meta-analysis
09
DOI 10.1080/14740338.2026.2704844
Open DOI
Safety profile of dual TIGIT and PD-L1 blockade with tiragolumab plus atezolizumab in solid tumors: a systematic review and meta-analysis of randomized controlled trials
Dual immune-checkpoint blockade targeting T-cell immunoreceptor with Ig and ITIM domains (TIGIT) and programmed death-ligand 1 (PD-L1) shows synergistic antitumor activity. However, its safety profile remains incompletely defined. Our sy...
10
DOI 10.1080/14740338.2026.2707152
Open DOI
Long-term efficacy and safety of intra-articular corticosteroid injections in patients with knee osteoarthritis
1. KOA is one of the most prevalent joint conditions worldwide, with a prevalence of more than 364 million cases of KOA and 29.5 million incident cases in 2019 alone [1]. Risk factors for osteoarth...
Bibliographical & Catalog Notes
Title from cover.
Vol. 1 complete in 4 issues.
Also issued online.